Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

Case Comprehensive Cancer Center (Case CCC)

Status: Terminated

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Leukemia

Treatments: Other: immunologic technique; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00918658

CASE-2Z08-CC502 (Other Identifier)

P30CA043703 (U.S. NIH Grant/Contract)

CASE2Z08 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors find better ways to treat the cancer.

PURPOSE: This research study is looking at natural killer cells in bone marrow and blood samples from patients with hematologic cancer and from patients who do not have cancer.

Full description

OBJECTIVES:

• To collect normal and malignant cells in bone marrow and peripheral blood samples from patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in cytotoxicity assays.
• To collect information about HLA type and immunophenotype of malignant cells as determined by clinical flow cytometry.

OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.

Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Enrollment: 34 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Meets one of the following criteria:

  • No evidence of malignancy

  • Diagnosis of one of the following:

    • Acute myeloid leukemia
    • Acute lymphoblastic leukemia
    • Chronic myelogenous leukemia
    • Multiple myeloma

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified

Trial design

34 participants in 2 patient groups

Patients with hematologic cancer

Description:

Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma

Treatment:

Other: immunologic technique

Other: biologic sample preservation procedure

Other: laboratory biomarker analysis

Patients without cancer

Description:

Patients who do not have cancer.

Treatment:

Other: immunologic technique

Other: biologic sample preservation procedure

Other: laboratory biomarker analysis